The drug is designed to treat patients with moderate to severe ulcerative colitis or Crohn’s disease who have failed to respond to one more standard therapies.
Entyvio is an integrin receptor antagonist developed by Takeda Pharmaceuticals.
More Articles on Gastroenterology:
GI/Endoscopy Center HIT: The Future is Here
ACGT, AGA, ASGE Meet With CMS to Discuss GI Value & Reimbursement: 4 Things to Know
The 3 Most Exciting Advances in Endoscope Reprocessing
